Sight Sciences, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Sight Sciences, Inc. has filed its 2023 10-K report detailing its fiscal year performance and financial standing.</b>

AI Summary

Sight Sciences, Inc. (SGHT) filed a Annual Report (10-K) with the SEC on March 13, 2024. Sight Sciences, Inc. filed its 2023 Form 10-K on March 13, 2024. The filing covers the fiscal year ending December 31, 2023. Key financial data and operational details for the fiscal year are presented. The company is incorporated in Delaware and headquartered in Menlo Park, CA. The filing includes information on various financial instruments and commitments.

Why It Matters

For investors and stakeholders tracking Sight Sciences, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Sight Sciences' financial health, operational activities, and strategic positioning for the fiscal year 2023, crucial for investors and stakeholders to assess performance and future outlook. The detailed financial statements and risk factors within the report offer insights into the company's market position, potential challenges, and compliance with regulatory requirements in the surgical and medical instruments sector.

Risk Assessment

Risk Level: medium — Sight Sciences, Inc. shows moderate risk based on this filing. The company's financial performance and future prospects are subject to market dynamics, competition, and regulatory approvals within the medical device industry, as indicated by the detailed risk factors in the 10-K.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Sight Sciences' current financial health and potential growth opportunities and challenges.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-13 — Filing Date (Date of submission)
• 001-40587 — SEC File Number (Company's SEC filing number)
• 0000950170-24-030278 — Accession Number (Unique identifier for the filing)

Key Players & Entities

• Sight Sciences, Inc. (company) — Filer name
• 2023-12-31 (date) — Fiscal year end
• 2024-03-13 (date) — Filing date
• Menlo Park, CA (location) — Business address
• 4040 Campbell Ave, Suite 100 (address) — Business address
• Hercules Capital Inc (company) — Mentioned in relation to credit agreements
• MidCap Financial Services (company) — Mentioned in relation to credit agreements
• 3841 (industry_code) — Standard Industrial Classification

FAQ

Risk Factors

• Credit Agreements [medium — financial]: The company has entered into various credit agreements, including with Hercules Capital Inc. and MidCap Financial Services, which may impose restrictions and covenants.
• Dry Eye Market [medium — market]: The company's products are targeted towards the dry eye market, which is subject to competition and market acceptance.
• Regulatory Compliance [high — regulatory]: As a medical device company, Sight Sciences is subject to stringent regulatory requirements for product development, manufacturing, and marketing.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-13: Filing Date — Date the 10-K was officially filed with the SEC.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 SGHT The Nasdaq Global Select Marke
• $8.28 — ce for the Registrant's common stock of $8.28 on that date. Shares of common stock he
• $6.0 billion — ("Dry Eye") segments are approximately $6.0 billion (with approximately $1.0 billion in the
• $1.0 billion — mately $6.0 billion (with approximately $1.0 billion in the combination cataract procedure s
• $5.0 billion — ination cataract procedure segment, and $5.0 billion in the standalone procedure segment) an
• $2.5 b — n the standalone procedure segment) and $2.5 billion, respectively. The combination ca

Filing Documents

• sght-20231231.htm (10-K) — 2182KB
• sght-ex4_3.htm (EX-4.3) — 30KB
• sght-ex10_14.htm (EX-10.14) — 56KB
• sght-ex21_1.htm (EX-21.1) — 5KB
• sght-ex23_1.htm (EX-23.1) — 2KB
• sght-ex24_1.htm (EX-24.1) — 48KB
• sght-ex31_1.htm (EX-31.1) — 18KB
• sght-ex31_2.htm (EX-31.2) — 19KB
• sght-ex32_1.htm (EX-32.1) — 8KB
• sght-ex32_2.htm (EX-32.2) — 8KB
• sght-ex97_1.htm (EX-97.1) — 33KB
• 0000950170-24-030278.txt (&nbsp;) — 8856KB
• sght-20231231.xsd (EX-101.SCH) — 1407KB
• sght-20231231_htm.xml (XML) — 1290KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 27 Item 1B. Unresolved Staff Comments 63 Item 1C. Cybersecurity 63 Item 2.

Properties

Properties 63 Item 3.

Legal Proceedings

Legal Proceedings 63 Item 4. Mine Safety Disclosures 64 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 65 Item 6. [Reserved] 65 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 66 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 75 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 76 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 99 Item 9A.

Controls and Procedures

Controls and Procedures 99 Item 9B. Other Information 100 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 100 PART III Item 10. Directors, Executive Officers and Corporate Governance 101 Item 11.

Executive Compensation

Executive Compensation 103 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 103 Item 13. Certain Relationships and Related Transactions, and Director Independence 103 Item 14. Principal Accountant Fees and Services 103 PART IV Item 15. Exhibits and Financial Statement Schedules 104 Item 16. Form 10-K Summary 104 1 Special Note Regarding Forward-Looking Statements Unless the context otherwise requires, references in this Annual Report on Form 10-K to the "Company," "Sight Sciences," "we," "us" and "our" refer to Sight Sciences, Inc. This Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (this "Annual Report on Form 10-K") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "hope," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: our ability to obtain and maintain sufficient reimbursement for our products, including ou

View Full Filing

View this 10-K filing on SEC EDGAR